CN103880702A - O-cinnamyl-fluorophenylsalicylamide compounds and application thereof in preparing anti-leukaemia drugs - Google Patents

Abstract

The invention discloses O-cinnamyl-fluorophenylsalicylamide compounds disclosed as Formula (I) and application thereof in preparing anti-leukaemia drugs. The invention provides a preparation method of the O-cinnamyl-fluorophenylsalicylamide compounds; the invention provides a new anti-human leukaemia drug with obvious activity, provides research basis for screening new drugs, and has important application prospects; and the preparation process is simple, and is beneficial to industrialized production.

Description

O-cinnamoyl-fluorophenyl salicylamide compounds and their application in the preparation of anti-leukemia drugs

(1) Technical field

The invention relates to an O-cinnamoyl-fluorophenyl salicylamide compound and its application in the preparation of anti-human leukemia drugs.

(2) Background technology

Leukemia is a kind of clonal malignant disease with abnormal hematopoietic stem cells. The leukemia cells in its clones lose the ability to further differentiate and mature and stagnate at different stages of cell development. In the bone marrow and other hematopoietic tissues, a large number of leukemia cells proliferate and accumulate and infiltrate other organs and tissues, and at the same time inhibit normal hematopoiesis. The clinical manifestations are anemia, bleeding, infection and infiltration of various organs. According to foreign statistics, leukemia accounts for about 3% of the total incidence of tumors, and is the most common malignant tumor in children and young people. Among the countries in the world, the incidence of leukemia is the highest in Europe and North America, with a mortality rate of 3.2-7.4/100,000 population. The incidence rate in Asia and South America is slightly lower, and the mortality rate is 2.8-4.5/100,000 population. Therefore, leukemia has become a major killer that seriously threatens the health and lives of people all over the world, and its danger cannot be underestimated.

Chinese patent CN102600181A "Application of (4-substituted benzoyl) phenyl salicylic amide compounds in the preparation of anti-leukemic drugs", CN102526077A "Application of phenylacetyl fluorophenyl salicylic amide compounds in the preparation of anti-leukemic drugs" respectively The O-benzoyl and O-phenylacetylfluorophenyl salicylamide compounds prepared from diflunisal as the parent of salicylic acid and their application in antineoplastic drugs were introduced.

Compared with benzoyl, cinnamoyl has larger steric volume and moderate molecular flexibility, which makes it more selective for the specific spatial structure of some cells; compared with phenylacetyl, it has a more complete large The electronic structure of the π bond will moderately change the pharmaceutical properties of the target molecule.

Therefore, it is of great significance to prepare a new fluorine-containing drug with anti-human leukemia activity by using cinnamoyl-p-fluorophenylsalicylic acid for structural modification.

(3) Contents of the invention

The object of the present invention is to provide a kind of O-cinnamoyl-fluorophenyl salicylamide compound and its application in the preparation of anti-human leukemia drugs.

The technical scheme adopted in the present invention is:

A kind of O-cinnamoyl-fluorophenyl salicylamide compound as shown in formula (I):

In formula (I), R is a benzyl group or a substituted phenyl group whose structure is shown in formula (A):

In formula (A), Q ₁ to Q ₅ are each independently H, methyl, fluorine, chlorine, nitro, methoxy or ethoxy.

Preferably, the R is preferably a substituted phenyl group with the structure shown in formula (A), and the corresponding O-cinnamoyl-fluorophenyl salicylamide compound is shown in formula (II):

Furthermore, the O-cinnamoyl-fluorophenyl salicylamide compound described in the present invention is preferably one of the compounds in Table 1:

Table 1:

compound R Q ₁ Q ₂ Q ₃ Q ₄ Q ₅ Ⅰ-1 / h h h h h Ⅰ-2 / _CH3 h h h h Ⅰ-3 / h _CH3 h h h Ⅰ-4 / h h _CH3 h h Ⅰ-5 / h h f h h Ⅰ-6 / Cl h h h h Ⅰ-7 / h Cl h h h Ⅰ-8 / h h Cl h h Ⅰ-9 / h NO ₂ h h h Ⅰ-10 / OCH ₃ h h h h Ⅰ-11 / OC ₂ H ₅ h h h h Ⅰ-12 / f h f h h Ⅰ-13 _{CH2C6H5 _ _} / / / / /

The present invention also provides the preparation method of the O-cinnamoyl-fluorophenyl salicylamide compound shown in formula (I): diflunisal shown in formula (III) and cinnamon shown in formula (IV) acyl chloride reaction to obtain O-cinnamoyl-fluorophenylsalicylic acid shown in formula (Ⅴ); then, O-cinnamoyl-fluorophenylsalicylic acid shown in formula (Ⅴ) and _SOCl2 to obtain formula ( Ⅵ) O-cinnamoyl-fluorophenylsalicyloyl chloride; finally, the O-cinnamoyl-fluorophenylsalicyloyl chloride shown in formula (Ⅵ) and the amine compound shown in formula (Ⅶ) undergo amidation reaction, The O-cinnamoyl-fluorophenyl salicylamide compound represented by the formula (I) is obtained. The equation of the reaction is shown in the following formula.

In formula (VII), R is a benzyl group or a substituted phenyl group whose structure is shown in formula (A):

In formula (A), Q ₁ to Q ₅ are each independently H, methyl, fluorine, chlorine, nitro, methoxy or ethoxy.

For related synthesis methods, refer to Chinese patents CN102010366A, CN102600181A, CN102526077A and the contents disclosed in Bioorg.Med.Chem.Lett.19(2), 516-519.

Specifically, the method is recommended to be carried out in accordance with the following steps:

(1) In toluene solvent, in the presence of catalyst A, add cinnamic acid and acyl chloride reagent A, heat to reflux, and carry out acyl chloride reaction, usually for 3-8 hours; after the reaction, distill off the solvent to obtain formula (IV) The cinnamoyl chloride shown is dissolved in an organic solvent A to obtain an acid chloride solution A for use;

The catalyst A is: DMF, pyridine or N,N-dimethylaniline;

The acid chloride reagent A is: thionyl chloride, phosphorus oxychloride or phosphorus pentachloride;

The organic solvent A is: tetrahydrofuran, butanone or toluene;

The ratio of the amount of the cinnamic acid to the amount of the acid chloride reagent A is 1:1-3, preferably 1:1.5-2.

(2) Dissolve the diflunisal (diflunisal) shown in the formula (Ⅲ) with the organic solvent B, add the organic amine A, mix well and add the acid chloride solution A prepared in step (1), The esterification reaction is carried out at room temperature, usually for 6-16 hours, and the obtained reaction liquid a is separated and processed after the reaction to obtain O-cinnamoyl-fluorophenylsalicylic acid represented by formula (V);

The organic amine A is: triethylamine or pyridine;

The organic solvent B is: tetrahydrofuran, butanone or toluene;

The ratio of the amount of diflunisalicylic acid represented by the formula (III) to the cinnamoyl chloride in the acid chloride solution A is 1:1-1.5. The amount of cinnamoyl chloride in the acid chloride solution A is measured as the amount of cinnamic acid.

The ratio of the amount of diflunisalic acid represented by the formula (III) to the organic amine A is 1:1-1.2.

The method for separating and treating the reaction liquid a is as follows: after the reaction, filter the reaction liquid a, add dilute hydrochloric acid to the filtrate, stir, crystallize, filter, wash the filter cake with ethanol, and dry to obtain O shown in formula (V). - Cinnamoyl-fluorophenylsalicylic acid.

(3) In toluene solvent, in the presence of catalyst B, the O-cinnamoyl-fluorophenylsalicylic acid prepared in step (2) is treated with acid chloride reagent B at a temperature of 60-100°C (preferably 80°C). Acyl chloride reaction, usually for 3 to 10 hours; after the reaction, the solvent is evaporated to obtain O-cinnamoyl-fluorophenylsalicyloyl chloride represented by formula (VI), which is dissolved in an organic solvent C to obtain an acid chloride solution B for use;

The catalyst B is: DMF, pyridine or N,N-dimethylaniline;

The acid chloride reagent B is: thionyl chloride, phosphorus oxychloride or phosphorus pentachloride;

The organic solvent C is: tetrahydrofuran, acetone, butanone or toluene;

The ratio of the amount of O-cinnamoyl-fluorophenylsalicylic acid to the acid chloride reagent B is 1:1-3, preferably 1:2.

(4) Add the amine compound represented by the formula (VII) into the organic solvent D, then add the acid chloride solution B prepared in step (3), and carry out the condensation reaction at room temperature, usually for 6 to 20 hours, and obtain The reaction liquid b is separated and processed to obtain O-cinnamoyl-fluorophenyl salicylamide compounds represented by formula (I).

The organic solvent D is: tetrahydrofuran, acetone, butanone or toluene;

The ratio of the amount of O-cinnamoyl-fluorophenylsalicyloyl chloride represented by the formula (VI) to the amine compound represented by the formula (VII) in the acid chloride solution B is 1:2-2.2. The amount of O-cinnamoyl-fluorophenylsalicylic acid represented by the formula (VI) in the acid chloride solution B is measured by the amount of O-cinnamoyl-fluorophenylsalicylic acid.

The method for separating and treating the reaction liquid b is as follows: after the reaction, filter the reaction liquid b, add water to the filtrate, stir, crystallize, filter, wash the filter cake with ethanol and recrystallize with butanone to obtain the compound shown in formula (I). O-cinnamoyl-fluorophenyl salicylamide compounds.

The present invention also provides the application of the O-cinnamoyl-fluorophenyl salicylamide compound in the preparation of anti-leukemia drugs. After testing, the O-cinnamoyl-fluorophenyl salicylamide compound of the present invention can obviously inhibit the growth of human leukemia cells at a certain concentration, and can be used as an anti-leukemia drug for the treatment of human leukemia. Preferably, the application of the O-cinnamoyl-fluorophenyl salicylamide compound in the preparation of anti-leukemia drugs, the O-cinnamoyl-fluorophenyl salicylamide compound is compound I-1, I-2, I-3, I-5, I-6, I-7, I-8, I-9, I-10, I-11 or -12, more preferably compounds I-1, I-2, I-8 , I-9 or I-10.

The beneficial effects of the present invention are mainly reflected in: (1) providing a kind of O-cinnamoyl-fluorophenyl salicylamide compound and its preparation method; (2) providing a new anti-leukemia activity The human leukemia drug provides a research basis for new drug screening and has great application prospects; (3) The preparation process of the compound is simple, which is conducive to industrial production.

(4) Specific implementation methods

The present invention is further described below in conjunction with specific embodiment, but protection scope of the present invention is not limited thereto:

Example 1: Synthesis of O-cinnamoyl-fluorophenylsalicylic acid (Ⅴ)

19.3g (0.13mol) cinnamic acid, 23.2g (0.195mol) SOCl2, 60ml toluene and 8 drops of DMF were dropped into the reaction flask, heated, refluxed for 6 hours, cooled, and evaporated to dryness under reduced pressure to obtain a reddish-brown oily liquid, which was used Dissolve in 20ml THF to prepare cinnamoyl chloride (IV) solution, set aside.

Add 25.0g (0.10mol) diflunisal, 60mlTHF, 9.6g (0.12mol) pyridine to another reaction flask, stir at room temperature for 30min, slowly add the cinnamoyl chloride solution prepared in the previous step under ice bath, and stir at room temperature overnight.

Suction filtration, add 200ml (1mol/L) dilute hydrochloric acid to the filtrate, stir, and precipitate a light yellow solid; suction filtration, wash the filter cake with ethanol, and dry to obtain the crude product of O-cinnamoyl-fluorophenylsalicylic acid (V) , yield: 86.4%, melting point: 192-195°C (uncorrected).

¹ H NMR spectrum analysis is as follows:

¹ H NMR(500MHz,DMSO,δppm):6.95(d,1H,J=16.0Hz,α-H),7.25(t,1H,J=8.5Hz,3′-H),7.42(d,1H, J=8.5Hz,3-H),7.43(t,1H,J=9.0Hz,5′-H),7.49(t,1H,J=8.5Hz,4′′-H),7.49(t,2H ,J=8.0Hz,3'',5''-H),7.70(q,1H,J=9.0Hz,6'-H),7.83(d,1H,J=8.5Hz,4-H), 7.85(d,2H,J=8.0Hz,2′′,6′′-H),7.88(d,1H,J=16.0Hz,β-H),8.07(s,1H,6-H),13.25 (s,1H,-COOH).

Example 2: Preparation of N-phenyl-O-cinnamoyl-fluorophenyl salicylamide (Ⅰ-1)

Put 7.6g (0.02mol) of O-cinnamoyl-fluorophenylsalicylic acid crude product (Ⅴ), 4.8g (0.04mol) of thionyl chloride, 40ml of toluene and 4 drops of DMF into the reaction flask, at 80°C (uncorrected ) for 6 hours, and evaporated to dryness under reduced pressure to obtain a light yellow solid, which was dissolved in 40ml of acetone to obtain a solution of O-cinnamoyl-fluorophenylsalicyloyl chloride (Ⅵ) for future use.

Under ice bath, add 3.7g (0.04mol) aniline/10ml acetone mixture to the prepared O-cinnamoyl-fluorophenyl salicyloyl chloride (Ⅵ) solution, react at room temperature for 10h; filter, add 100ml water to the filtrate , stirred, crystallized, filtered, the filter cake was washed with ethanol, and then recrystallized with butanone to obtain white N-phenyl-O-cinnamoyl-fluorophenyl salicylamide (Ⅰ-1), melting point: 149-152°C ( Uncorrected), yield: 51.6%.

¹ H NMR spectrum analysis is as follows:

¹ H NMR (500MHz, CDCl ₃ , δppm): 6.70(d, 1H, J=16.0Hz, α-H), 6.95(t, 1H, J=8.5Hz, 3′-H), 6.99(t, 1H ,J=8.5Hz,5′-H),7.13(t,1H,J=7.5Hz,4′′′-H),7.13(t,2H,J=7.5Hz,3′′′,5′′ ′-H),7.34(d,1H,J=8.5Hz,3-H),7.45(t,1H,J=8.5Hz,4′′-H),7.46(t,2H,J=7.5Hz, 3'',5''-H),7.48(q,1H,J=9.0Hz,6'-H),7.59(dd,2H,J=8.0Hz,2'',6''-H), 7.61(d,2H,J=7.5Hz,2''',6'''-H),7.70(d,1H,J=8.5Hz,4-H),7.97(d,1H,J=16.0Hz ,β-H),8.08(s,1H,6-H),8.26(s,1H,-NH-).

Example 3: Preparation of N-(2-methylphenyl)-O-cinnamoyl-fluoro salicylamide (Ⅰ-2)

Replace the aniline in Example 2 with 0.04mol2-methylaniline, and other operations are the same as in Example 2 to obtain N-(2-methylphenyl)-O-cinnamoyl-fluoro-salicylamide (I-2), Melting point: 139-143°C (uncorrected), Yield: 37.2%.

¹ H NMR spectrum analysis is as follows:

¹ H NMR(500MHz,CDCl ₃ ,δppm):2.32(s,3H,-CH ₃ ),6.69(d,1H,J=16.0Hz,α-H),6.96(t,1H,J=8.5Hz, 3′-H),7.01(t,1H,J=8.0Hz,5′-H),7.10(t,1H,J=7.5Hz,4′′′-H),7.20(d,1H,J= 7.5Hz,6'''-H),7.24(t,1H,J=8.0Hz,5'''-H),7.33(d,1H,J=8.5Hz,3-H),7.44(t, 1H,J=8.0Hz,4''-H),7.45(t,2H,J=7.5Hz,3'',5''-H),7.49(q,1H,J=8.5Hz,6'- H),7.58(dd,2H,J=7.5Hz,2'',6''-H),7.71(d,1H,J=8.5Hz,4-H),7.95(d,1H,J=16.0 Hz, β-H), 7.97 (d, 1H, J=7.5Hz, 3′′′-H), 8.01 (s, 1H, -NH-), 8.10 (s, 1H, 6-H).

Example 4: Preparation of N-(3-methylphenyl)-O-cinnamoyl-fluoro salicylamide (Ⅰ-3)

Replace the aniline in Example 2 with 0.04mol3-methylaniline, and other operations are the same as in Example 2 to obtain N-(3-methylphenyl)-O-cinnamoyl-fluoro-salicylamide (I-3), Melting point: 164-168°C (uncorrected), Yield: 44.7%.

¹ H NMR spectrum analysis is as follows:

¹ H NMR(500MHz,CDCl ₃ ,δppm):2.30(s,3H,-CH ₃ ),6.71(d,1H,J=16.0Hz,α-H),6.94(d,1H,J=7.5Hz, 4′′′-H),6.97(t,1H,J=8.5Hz,3′-H),7.01(t,1H,J=8.0Hz,5′-H),7.21(t,1H,J= 8.0Hz,5'''-H),7.35(d,1H,J=8.0Hz,3-H),7.39(d,1H,J=8.5Hz,6'''-H),7.44(s, 1H,2'''-H),7.45(t,1H,J=7.5Hz,4''-H),7.46(t,2H,J=7.5Hz,3'',5''-H), 7.48(q,1H,J=8.5Hz,6′-H),7.60(dd,2H,J=7.5Hz,2′′,6′′-H),7.71(d,1H,J=8.5Hz, 4-H), 7.98 (d, 1H, J=16.0Hz, β-H), 8.08 (s, 1H, 6-H), 8.23 (s, 1H, -NH-).

Example 5: Preparation of N-(4-methylphenyl)-O-cinnamoyl-fluoro salicylamide (I-4)

Replace the aniline in Example 2 with 0.04mol4-methylaniline, and other operations are the same as in Example 2 to obtain N-(4-methylphenyl)-O-cinnamoyl-fluoro-salicylamide (I-4), Melting point: 148-152°C (uncorrected), Yield: 49.0%.

1H NMR spectrum analysis is as follows:

¹ H NMR(500MHz,CDCl ₃ ,δppm):2.31(s,3H,-CH ₃ ),6.69(d,1H,J=16.0Hz,α-H),6.95(t,1H,J=9.0Hz, 3′-H), 6.99(t, 1H, J=9.0Hz, 5′-H), 7.13(d, 2H, J=8.5Hz, 3′′′, 5′′′-H), 7.33(d ,1H,J=8.5Hz,3-H),7.43(t,1H,J=8.0Hz,4′′-H),7.46(t,2H,J=7.0Hz,3′′,5′′- H),7.47(q,1H,J=8.0Hz,6′-H),7.49(d,2H,J=8.5Hz,2′′′,6′′′-H),7.58(dd,2H, J=8.0Hz,2'',6''-H),7.69(d,1H,J=8.5Hz,4-H),7.96(d,1H,J=16.0Hz,β-H),8.06( s,1H,6-H), 8.24(s,1H,-NH-).

Example 6: Preparation of N-(4-fluorophenyl)-O-cinnamoyl-fluorosalicylamide (I-5)

The aniline in Example 2 was replaced with 0.04mol 4-fluoroaniline, and other operations were the same as in Example 2 to obtain N-(4-fluorophenyl)-O-cinnamoyl-fluoro-salicylamide (I-5), melting point: 168-171°C (uncorrected), Yield: 45.7%.

¹ H NMR spectrum analysis is as follows:

¹ H NMR (500MHz, CDCl ₃ , δppm): 6.69(d, 1H, J=16.0Hz, α-H), 6.96(t, 1H, J=8.5Hz, 3′-H), 7.01(t, 1H ,J=8.5Hz,5′-H),7.02(t,2H,J=9.0Hz,3′′′,5′′′-H),7.33(d,1H,J=8.0Hz,3-H ),7.45(t,1H,J=7.5Hz,4′′-H),7.47(t,2H,J=8.0Hz,3′′,5′′-H),7.48(q,1H,J= 8.0Hz,6'-H),7.56(dd,2H,J=9.0Hz,2''',6'''-H),7.60(dd,2H,J=7.5Hz,2'',6' ′-H),7.70(d,1H,J=8.5Hz,4-H),7.97(d,1H,J=16.0Hz,β-H),8.05(s,1H,6-H),8.23( s,1H,-NH-).

Example 7: Preparation of N-(2-chlorophenyl)-O-cinnamoyl-fluoro salicylamide (I-6)

The aniline in Example 2 was replaced with 0.04mol 2-chloroaniline, and other operations were the same as in Example 2 to obtain N-(2-chlorophenyl)-O-cinnamoyl-fluoro-salicylamide (I-6), melting point: 181-184°C (uncorrected), Yield: 74.6%.

1H NMR spectrum analysis is as follows:

¹ H NMR (500MHz, CDCl ₃ , δppm): 6.78(d, 1H, J=16.0Hz, α-H), 6.97(t, 1H, J=8.5Hz, 3′-H), 7.01(t, 1H ,J=8.5Hz,5′-H),7.07(t,1H,J=7.5Hz,4′′′-H),7.32(t,1H,J=7.5Hz,5′′′-H), 7.37(d,1H,J=8.5Hz,3-H),7.39(d,1H,J=7.5Hz,3′′′-H),7.45(t,1H,J=8.0Hz,4′′- H),7.46(t,2H,J=7.0Hz,3′′,5′′-H),7.49(q,1H,J=8.5Hz,6′-H),7.60(dd,2H,J= 7.5Hz,2'',6''-H),7.74(d,1H,J=8.5Hz,4-H),7.95(d,1H,J=16.0Hz,β-H),8.21(s, 1H, 6-H), 8.60 (d, 1H, J=8.5Hz, 6'''-H), 8.99 (s, 1H, -NH-).

Example 8: Preparation of N-(3-chlorophenyl)-O-cinnamoyl-fluorosalicylamide (Ⅰ-7)

Replace the aniline in embodiment 2 with 0.04mol3-chloroaniline, and other operations are with embodiment 2,

N-(3-Chlorophenyl)-O-cinnamoyl-fluorosalicylamide (I-7) was obtained, melting point: 179-183°C (uncorrected), yield: 40.8%.

¹ H NMR spectrum analysis is as follows:

¹ H NMR (500MHz, CDCl ₃ , δppm): 6.69(d, 1H, J=16.0Hz, α-H), 6.96(t, 1H, J=8.5Hz, 3′-H), 7.01(t, 1H ,J=8.0Hz,5′-H),7.10(d,1H,J=7.5Hz,4′′′-H),7.24(t,1H,J=7.5Hz,5′′′-H), 7.34(d,1H,J=8.5Hz,3-H),7.44(d,1H,J=8.5Hz,6′′′-H),7.45(t,1H,J=8.5Hz,4′′- H),7.46(t,2H,J=7.5Hz,3′′,5′′-H),7.47(q,1H,J=8.5Hz,6′-H),7.60(dd,2H,J= 8.0Hz,2'',6''-H),7.71(d,1H,J=8.5Hz,4-H),7.74(s,1H,2'''-H),7.97(d,1H, J=16.0Hz, β-H), 8.05(s, 1H, 6-H), 8.31(s, 1H, -NH-).

Example 9: Preparation of N-(4-chlorophenyl)-O-cinnamoyl-fluorosalicylamide (I-8)

Replace the aniline in Example 2 with 0.04mol 4-chloroaniline, and other operations are the same as in Example 2 to obtain N-(4-chlorophenyl)-O-cinnamoyl-fluoro salicylamide (I-8), melting point: 176-180°C (uncorrected), yield: 42.9%.

¹ H NMR spectrum analysis is as follows:

¹ H NMR(500MHz,CDCl ₃ ,δppm):6.68(d,1H,J=16.0Hz,α-H),6.96(t,1H,J=8.5Hz,3′-H),7.01(t,1H ,J=8.5Hz,5′-H),7.29(d,2H,J=9.0Hz,3′′′,5′′′-H),7.34(d,1H,J=8.0Hz,3-H ),7.45(t,1H,J=8.0Hz,4′′-H),7.47(t,2H,J=7.5Hz,3′′,5′′-H),7.48(q,1H,J= 8.5Hz, 6'-H), 7.56(d, 2H, J=8.5Hz, 3''', 5'''-H), 7.59(dd, 2H, J=8.0Hz, 2'', 6' ′-H),7.71(d,1H,J=8.5Hz,4-H),7.96(d,1H,J=16.0Hz,β-H),8.05(s,1H,6-H),8.29( s,1H,-NH-).HPLC:

Example 10: Preparation of N-(3-nitrophenyl)-O-cinnamoyl-fluorosalicylamide (I-9)

Replace the aniline in Example 2 with 0.04mol 3-nitroaniline, and other operations are the same as in Example 2 to obtain N-(3-nitrophenyl)-O-cinnamoyl-fluoro-salicylamide (I-9), Melting point: 186-188°C (uncorrected), Yield: 53.0%.

¹ H NMR spectrum analysis is as follows:

¹ H NMR (500MHz, CDCl ₃ , δppm): 6.72(d, 1H, J=16.0Hz, α-H), 6.97(t, 1H, J=8.5Hz, 3′-H), 7.02(t, 1H ,J=8.0Hz,5′-H),7.37(d,1H,J=8.0Hz,3-H),7.46(t,1H,J=8.0Hz,4′′-H),7.47(t, 2H,J=7.0Hz,3'',5''-H),7.49(q,1H,J=8.0Hz,6'-H),7.51(t,1H,J=8.5Hz,5''' -H),7.62(dd,2H,J=7.5Hz,2′′,6′′-H),7.74(d,1H,J=8.0Hz,4-H),7.98(d,1H,J= 8.5Hz,6'''-H),8.00(d,1H,J=16.0Hz,β-H),8.07(d,1H,J=9.0Hz,4'''-H),8.09(s, 1H, 6-H), 8.42 (s, 1H, 2'''-H), 8.57 (s, 1H, -NH-).

Example 11: Preparation of N-(2-methoxyphenyl)-O-cinnamoyl-fluorosalicylamide (I-10)

Replace the aniline in Example 2 with 0.04mol2-methoxyaniline, and other operations are the same as in Example 2 to obtain N-(2-methoxyphenyl)-O-cinnamoyl-fluorine base salicylamide (I-10 ), melting point: 138-142°C (uncorrected), yield: 56.6%.

1H NMR spectrum analysis is as follows:

¹ H NMR(500MHz,CDCl ₃ ,δppm):3.82(s,3H,-CH ₃ ),6.74(d,1H,J=16.0Hz,α-H),6.87(d,1H,J=8.0Hz, 3′′′-H),6.96(t,1H,J=8.5Hz,3′-H),7.00(t,1H,J=8.0Hz,5′-H),7.02(t,1H,J= 7.5Hz,5'''-H),7.07(t,1H,J=7.5Hz,4'''-H),7.38(d,1H,J=8.0Hz,3-H),7.44(t, 1H,J=8.0Hz,4''-H),7.46(t,2H,J=7.0Hz,3'',5''-H),7.49(q,1H,J=8.5Hz,6'- H),7.58(dd,2H,J=7.5Hz,2'',6''-H),7.71(d,1H,J=8.5Hz,4-H),7.95(d,1H,J=16.0 Hz, β-H), 8.20 (s, 1H, 6-H), 8.58 (d, 1H, J=7.5Hz, 6′′′-H), 9.05 (s, 1H, -NH-).

Example 12: Preparation of N-(2-ethoxyphenyl)-O-cinnamoyl-fluorosalicylamide (I-11)

Replace the aniline in Example 2 with 0.04mol2-ethoxyaniline, and other operations are the same as in Example 2 to obtain N-(2-ethoxyphenyl)-O-cinnamoyl-fluorine salicylamide (I-11 ), melting point: 125-127°C (uncorrected), yield: 67.1%.

¹ H NMR spectrum analysis is as follows:

¹ H NMR (500MHz, CDCl ₃ , δppm): 1.45(t, 3H, J=7.0Hz, -CH3), 4.12(q, 2H, J=7.0Hz, -CH ₂ -), 6.72(d, 1H, J=16.0Hz,α-H),6.88(d,1H,J=8.0Hz,3′′′-H),6.96(t,1H,J=8.5Hz,3′-H),7.00(t, 1H, J=8.0Hz, 5′′′-H), 7.01(t, 1H, J=8.5Hz, 5′-H), 7.06(t, 1H, J=8.0Hz, 4′′′-H) ,7.39(d,1H,J=8.5Hz,3-H),7.43(t,1H,J=8.0Hz,4′′-H),7.44(t,2H,J=7.0Hz,3′′, 5''-H),7.49(q,1H,J=8.5Hz,6'-H),7.55(dd,2H,J=7.5Hz,2'',6''-H),7.70(d, 1H,J=8.5Hz,4-H),7.91(d,1H,J=16.0Hz,β-H),8.11(s,1H,6-H),8.58(d,1H,J=7.5Hz, 6'''-H), 8.92 (s, 1H, -NH-).

Example 13: Preparation of N-(2,4-difluorophenyl)-O-cinnamoyl-fluorosalicylamide (I-12)

Replace the aniline in Example 2 with 0.04mol2,4-difluoroaniline, and other operations are the same as in Example 2 to obtain N-(2,4-difluorophenyl)-O-cinnamoyl-fluoro-salicylamide (Ⅰ -12), melting point: 181-183°C (uncorrected), yield: 35.0%.

¹ H NMR spectrum analysis is as follows:

¹ H NMR (500MHz, CDCl ₃ , δppm): 6.76(d, 1H, J=16.0Hz, α-H), 6.89(t, 1H, J=8.5Hz, 3′′′-H), 6.92(t ,1H,J=8.0Hz,3′-H),6.97(t,1H,J=9.0Hz,5′′′-H),7.01(t,1H,J=8.0Hz,5′-H), 7.38(d,1H,J=8.5Hz,3-H),7.47(t,1H,J=8.0Hz,4′′-H),7.49(t,2H,J=7.5Hz,3′′,5 ''-H),7.50(q,1H,J=9.0Hz,6'-H),7.63(dd,2H,J=7.5Hz,2'',6''-H),7.74(d,1H ,J=8.5Hz,4-H),7.98(d,1H,J=16.0Hz,β-H),8.24(s,1H,6-H),8.51(q,1H,J=9.0Hz,6 '''-H), 8.82 (s, 1H, -NH-).

Example 14: Preparation of N-benzyl-O-cinnamoyl-fluorosalicylamide (I-13)

Replace the aniline in Example 2 with 0.04mol benzylamine, and other operations are the same as in Example 2 to obtain N-benzyl-O-cinnamoyl-fluoro-salicylamide (I-13), melting point: 140-143°C (not Correction), yield: 56.5%.

¹ H NMR spectrum analysis is as follows:

¹ H NMR(500MHz,CDCl ₃ ,δppm):4.62(s,2H,-CH ₂ -),6.45(d,1H,J=16.0Hz,α-H),6.76(s,1H,-NH-) ,6.95(t,1H,J=8.5Hz,3′-H),6.99(t,1H,J=8.5Hz,5′-H),7.14(t,1H,J=7.0Hz,4′′′ -H),7.21(t,2H,J=7.0Hz,3′′′,5′′′-H),7.27(d,1H,J=8.5Hz,3-H),7.31(t,2H, J=7.0Hz,2''',6'''-H),7.46(t,1H,J=8.0Hz,4''-H),7.47(t,2H,J=7.0Hz,3''-H) ,5''-H),7.48(q,1H,J=8.5Hz,6'-H),7.51(dd,2H,J=8.0Hz,2'',6''-H),7.66(d ,1H,J=8.5Hz,4-H),7.80(d,1H,J=16.0Hz,β-H),8.06(s,1H,6-H).

Embodiment 15～27: antitumor activity test

Anti-tumor activity test in vitro (Note: This test method, called MTT method, is a mature method.)

A. Principle: Succinate dehydrogenase in the mitochondria of living cells can reduce exogenous thiazolan (MTT) to water-insoluble blue-purple crystalline formazan (Formazan) and deposit in cells, while dead cells have no such function. Dimethyl sulfoxide (DMSO) can dissolve formazan in cells, and the absorbance value of formazan at a wavelength of 490nm is measured with an enzyme-linked immunosorbent detector, which can indirectly reflect the proliferation and quantity changes of cells. Within a certain cell number range, the amount of MTT crystal formation is proportional to the cell number.

B. Cells: human leukemia cell line (HL-60, purchased from Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences)

C. Experimental steps

1) Sample preparation: Take the compounds I-1~I-13 and cisplatin (control sample) prepared in Examples 2~14, dissolve each 1 mg sample with 20 μL DMSO, and then take 2 μL with 1000 μL culture medium (see the following steps (2) Preparation of culture medium in cell culture) diluted to prepare a 100 μg/mL sample solution, and then serially diluted with culture medium to use concentrations of 10 μg/mL and 1 μg/mL.

Preparation of 5mg/mL MTT: MTT solution was prepared with physiological saline at a concentration of 5mg/mL.

2) Cell culture

Preparation of culture medium: 800,000 units of penicillin, 1.0 g of streptomycin, and 10% inactivated calf serum were contained in 1000 mL of DMEM culture liquid (Gibco Company).

Cell culture: Inoculate tumor cell HL-60 in culture medium, culture in 37°C (uncorrected), 5% CO2 incubator, and passage for 3-5 days.

3) Determination of the inhibitory effect of samples on tumor cell growth

The cells were digested with ethylenediaminetetraacetic acid (EDTA)-trypsin digestion solution (0.25% trypsin, 0.02% EDTA, prepared with Hank's buffer), and diluted with culture medium to a cell concentration of 1×10 ⁶ /mL, adding Put it into a 96-well cell culture plate, 100 μL per well, culture in a 37°C (uncorrected), 5% CO ₂ incubator for 24 hours, pour out the culture solution, add the sample diluted with the culture solution, 200 μL per well, each The concentration was increased to 3 wells, cultured in a 37°C (uncorrected), 5% CO ₂ incubator, 72h later, 5mg/mL MTT was added to the cell culture wells, 10μL per well, and incubated at 37°C (uncorrected) for 3h, Add DMSO, 150 μL per well, oscillate with a shaker (Haimen Kylin Medical Instrument Factory, QL-9001) to completely dissolve formazan, and detect at a wavelength of 490 nm with an enzyme-linked immunosorbent assay (BIO-RAD, USA, Model 680) absorbance value. Cells cultured in culture medium containing cisplatin control samples and the same concentration of DMSO under the same conditions were used as blank controls, and the inhibitory rate of the samples on tumor cell growth was calculated according to the formula (1), and the inhibitory rates of the compounds on cell growth at various concentrations were calculated. The half-maximum inhibitory concentration (IC ₅₀ ) of each sample was calculated with SPSS software (purchased from SPSS Company, USA), and the results are shown in Table 2:

Calculation formula: inhibition rate (%) = (OD _blank - OD _sample ) / OD _blank × 100% formula (1)

Table 2: IC ₅₀ (mg/L) of each compound on HL-60

Example compound IC ₅₀ mg/L evaluate 15 Ⅰ-1 7.16 efficient 16 Ⅰ-2 7.28 efficient 17 Ⅰ-3 14.78 Weak

18 Ⅰ-4 32.81 invalid 19 Ⅰ-5 16.29 Weak 20 Ⅰ-6 13.28 Weak twenty one Ⅰ-7 12.31 Weak twenty two Ⅰ-8 6.91 efficient twenty three Ⅰ-9 8.95 efficient twenty four Ⅰ-10 8.48 efficient 25 Ⅰ-11 12.82 Weak 26 Ⅰ-12 14.01 Weak 27 Ⅰ-13 45.98 invalid

It can be seen from Table 2 that according to the evaluation criteria of anticancer activity, compounds Ⅰ-1, Ⅰ-2, Ⅰ-8, Ⅰ-9, and Ⅰ-10 have good anti-HL-60 leukemia cell activity, and compound Ⅰ -3, Ⅰ-5, Ⅰ-6, Ⅰ-7, Ⅰ-11 and -12 have certain activity against HL-60 leukemia cells.

Claims (5)

1. the O-cinnyl-fluorobenzene salicylamide compound as shown in formula I:

In formula I, R is benzyl or structure suc as formula the substituted-phenyl shown in (A):

In formula (A), Q ₁～Q ₅independent is separately H, methyl, fluorine, chlorine, nitro, methoxy or ethoxy.

2. O-cinnyl-fluorobenzene salicylamide compound as claimed in claim 1, it is characterized in that described R be structure suc as formula the substituted-phenyl shown in (A), described O-cinnyl-fluorobenzene salicylamide compound is as shown in formula II:

3. O-cinnyl-fluorobenzene salicylamide compound as claimed in claim 2, is characterized in that described O-cinnyl-fluorobenzene salicylamide compound is one of following table compound:

Compound Q ₁ Q ₂ Q ₃ Q ₄ Q ₅ Ⅰ-1 H H H H H Ⅰ-2 CH ₃ H H H H

Ⅰ-3 H CH ₃ H H H Ⅰ-5 H H F H H Ⅰ-6 Cl H H H H Ⅰ-7 H Cl H H H Ⅰ-8 H H Cl H H Ⅰ-9 H NO ₂ H H H Ⅰ-10 OCH ₃ H H H H Ⅰ-11 OC ₂H ₅ H H H H Ⅰ-12 F H F H H

4. O-cinnyl-fluorobenzene salicylamide compound as claimed in claim 3, is characterized in that described O-cinnyl-fluorobenzene salicylamide compound is I-1, I-2, I-8, I-9 or I-10.

5. the O-cinnyl-fluorobenzene salicylamide compound as described in one of claim 1-4 is in the application of preparing in anti-leukemia medicine.